Insurance and access implications of an over-the-counter switch for a progestin-only pill

Perspectives on Sexual and Reproductive Health

Volumn 45, Issue 3, 2013, Pages 164-169

  Mcintosh, Jennifer ^a   Wahlin, Britt ^b   Grindlay, Kate ^b   Batchelder, Myra ^c   Grossman, Daniel ^c  

^a HOSPITAL CLÍNIC   (Spain)

^b IBIS REPRODUCTIVE HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; NON PRESCRIPTION DRUG; ORAL CONTRACEPTIVE AGENT;

ARTICLE; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; INSURANCE; PREGNANCY; UNITED STATES; UNPLANNED PREGNANCY;

CONTRACEPTIVES, ORAL; FEMALE; HEALTH CARE REFORM; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; NONPRESCRIPTION DRUGS; PREGNANCY; PREGNANCY, UNPLANNED; PROGESTINS; UNITED STATES;

EID: 84883818852     PISSN: 15386341     EISSN: 19312393     Source Type: Journal    
DOI: 10.1363/4516413     Document Type: Article

References (54)

1. Shah PS et al., Intention to become pregnant and low birth weight and preterm birth: a systematic review, Maternal and Child Health Journal, 2011, 15(2):205-216.
2. Dye TD et al., Unintended pregnancy and breast-feeding behavior, American Journal of Public Health, 1997, 87(10):1709-1711.
3. Cheng D et al., Unintended pregnancy and associated maternal preconception, prenatal and postpartum behaviors, Contraception, 2009, 79(3):194-198.
4. U.S. Department of Health and Human Services (DHHS), Developing Healthy People 2020, 2010, , accessed Apr. 20, 2012.
5. DHHS, Healthy People 2000: National Health Promotion and Disease Prevention Objectives, Washington, DC: U.S. Government Printing Office, 1990.
6. DHHS, Promoting Health/Preventing Disease: Objectives for the Nation, Washington, DC: U.S. Government Printing Office, 1980.
7. Jones J, Mosher W and Daniels K, Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995, National Health Statistics Reports, 2012, No. 60, , accessed May 30, 2013.
8. Mosher WD and Jones J, Use of contraception in the United States: 1982-2008, Vital and Health Statistics, 2010, Series 23, No. 29, , accessed May 30, 2013.
9. Grossman D, Over-the-counter access to oral contraceptives, Expert Review of Obstetrics & Gynecology, 2011, 6(5):501-508.
10. Trussell J et al., Should oral contraceptives be available without prescription? American Journal of Public Health, 1993, 83(8):1094-1099.
11. Gianfrancesco F, Manning B and Wang R, Effects of prescription to OTC switches on out-of-pocket health care costs and utilization, Drug Benefit Trends, 2002, 14(3):13-30 & 44.
12. Grossman D, Should the contraceptive pill be available without prescription? Yes, BMJ, 2008, doi: 10.1136/bmj.a3044, accessed Oct. 1, 2012.
13. Landau SC, Tapias MP and McGhee BT, Birth control within reach: a national survey on women's attitudes toward and interest in pharmacy access to hormonal contraception, Contraception, 2006, 74(6):463-470.
14. Smith JD and Oakley D, Why do women miss oral contraceptive pills? An analysis of women's self-described reasons for missed pills, Journal of Midwifery & Women's Health, 2005, 50(5):380-385.
15. Potter JE et al., Continuation of prescribed compared with over-the-counter oral contraceptives, Obstetrics & Gynecology, 2011, 117(3):551-557.
16. Grossman D et al., Interest in over-the-counter access to oral contraceptives among women in the United States, Contraception, 2013, doi: 10.1016/j.contraception.2013.04.005, accessed July 1, 2013.
17. White K et al., Contraindications to progestin-only oral contraceptive pills among reproductive-aged women, Contraception, 2012, 86(3):199-203.
18. Liang SY, Grossman D and Phillips KA, User characteristics and out-of-pocket expenditures for progestin-only versus combined oral contraceptives, Contraception, 2012, 86(6):666-672.
19. Grimes DA et al., Progestin-only pills for contraception, Cochrane Database of Systematic Reviews, 2010, Issue 1, No. CD007541.
20. Cohen JP, Paquette C and Cairns CP, Switching prescription drugs to over the counter, BMJ (Clinical Research Ed.), 2005, 330(7481):39-41.
21. Andrade SE, Gurwitz JH and Fish LS, The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of H2-receptor antagonists, Medical Care, 1999, 37(4):424-430.
22. Gurwitz JH, McLaughlin TJ and Fish LS, The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of vaginal antifungal products, Health Services Research, 1995, 30(5):672-685.
23. Lipsky MS, Waters T and Sharp LK, Impact of vaginal antifungal products on utilization of health care services: evidence from physician visits, Journal of the American Board of Family Practice, 2000, 13(3):178-182.
24. Sullivan PW, Nair KV and Patel BV, The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy, American Journal of Managed Care, 2005, 11(6):374-382.
25. Lundberg L and Isacson D, The impact of over-the-counter availability of nasal sprays on sales, prescribing, and physician visits, Scandinavian Journal of Primary Health Care, 1999, 17(1):41-45.
26. Aventis Pharmaceuticals, Managed Care Digest Series 2002, 2002, , accessed May 30, 2013.
27. Sanofi Pharmaceuticals, Managed Care Digest Series, HMO PPO Digest, 2012, , accessed May 30, 2013.
28. McIntosh J, Tsikitas L and Dennis A, Low-income women's access to contraception after health care reform in Massachusetts, Journal of the American Pharmacists' Association, 2012, 52(3):349-357.
29. Guttmacher Institute, Insurance coverage of contraceptives, State Policies in Brief (as of June 2013), 2013, , accessed July 1, 2013.
30. Social Security Act, 1927(d)(2)(G).
31. National Pharmaceutical Association, Pharmaceutical Benefits Under State Medical Assistance Programs, Reston, VA: National Pharmaceutical Association, 2007.
32. Ranji U et al., State Medicaid Coverage of Family Planning Services: Summary of State Survey Findings, Menlo Park, CA: Kaiser Family Foundation, 2009.
33. National Health Law Program, State Medicaid coverage of emergency contraception (EC) as an over-the-counter (OTC) drug, 2007, , accessed Sept. 17, 2012.
34. U.S. Department of Veterans Affairs, VA national formulary, 2012, , accessed Jan. 5, 2013.
35. U.S. Department of Veterans Affairs, Veterans health benefits guide, no date, , accessed Jan. 5, 2013.
36. Tricare, Over-the-counter medication demonstration project, no date, , accessed Aug. 7, 2012.
37. Indian Health Service, Indian health manual, no date, , accessed Jan. 5, 2013.
38. Indian Health Service, National Pharmacy & Therapeutics Committee, IHS national core formulary, no date, , accessed Jan. 5, 2013.
39. National Institute for Reproductive Health, Expanding public health insurance coverage for EC, 2010, , accessed Aug. 10, 2012.
40. DHHS, The health care law & you: preventive care, no date, , accessed Aug. 7, 2012.
41. Institute of Medicine, Clinical Preventive Services for Women: Closing the Gaps, Washington, DC: National Academies Press, 2011.
42. DHHS, Women's preventive services: required health plan coverage guidelines, 2011, , accessed Aug. 7, 2011.
43. U.S. Department of Labor, FAQs About Affordable Care Act Implementation (Part XII), Washington, DC: U.S. Department of Labor, 2013, , accessed Feb. 24, 2013.
44. Appleby J, Five questions about the health law's mandate to cover birth control, Kaiser Health News, 2012, , accessed May 30, 2013.
45. Schwarz EB et al., Computer-assisted provision of hormonal contraception in acute care settings, Contraception, 2013, 87(2):242-250.
46. Department of the Treasury, Department of Labor and DHHS, Certain preventive services under the Affordable Care Act, Federal Register, 2012, 77(55):16501-16508, , accessed May 30, 2013.
47. West DS, Johnson JT and Hong SH, A 30-month evaluation of the effects on the cost and utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan, Journal of Managed Care Pharmacy, 2006, 12(1):25-32.
48. Trygstad TK, Hansen RA and Wegner SE, Evaluation of product switching after a state Medicaid program began covering -loratadine OTC 1 year after market availability, Journal of Managed Care Pharmacy, 2006, 12(2):108-120.
49. Carlton RI et al., Review of outcomes associated with formulary restrictions: focus on step therapy, American Journal of Pharmacy Benefits, 2010, 2(1):50-58.
50. Cox ER, Henderson R and Motheral BR, Health plan member experience with point-of-service prescription step therapy, Journal of Managed Care Pharmacy, 2004, 10(4):291-298.
51. Lu CY et al., Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness, Medical Care, 2010, 48(1):4-9.
52. Zhang Y et al., Effects of prior authorization on medication discontinuation among Medicaid beneficiaries with bipolar disorder, Psychiatric Services, 2009, 60(4):520-527.
53. Jacobson Vann JC et al., Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program, Journal of Managed Care Pharmacy, 2010, 16(4):250-263.
54. National Health Law Program, Public Hearing Comments Before the FDA Advisory Committee for Reproductive Health Drugs: New Drug Application (NDA) 22-474, Ulipristal Acetate Tablets (30 mgs)-"Ella" Emergency Contraceptive, 2010, , accessed Jan. 7, 2013.